UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US

JAMA network open, 2020-10, Vol.3 (10), p.e2021476

2020

Volltextzugriff (PDF)

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis

PloS one, 2020-06, Vol.15 (6), p.e0234065

2020

Volltextzugriff (PDF)

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

BMJ open, 2020-06, Vol.10 (6), p.e038863-e038863

2020

Volltextzugriff (PDF)

National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

Journal of the American Heart Association, 2022-05, Vol.11 (9), p.e023811-e023811

2022

Volltextzugriff (PDF)

Clinical trial registration and reporting: a survey of academic organizations in the United States

BMC medicine, 2018-05, Vol.16 (1), p.60-60, Article 60

2018

Volltextzugriff (PDF)

Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States

Annals of internal medicine, 2021-03, Vol.174 (3), p.428-430

2021

Volltextzugriff (PDF)

CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1468-1468

2021

Volltextzugriff (PDF)

Correction to: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol

Systematic reviews, 2018-03, Vol.7 (1), p.48-48, Article 48

2018

Volltextzugriff (PDF)

Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey

Drug and alcohol dependence, 2021-08, Vol.225, p.108811-108811, Article 108811

2021

Volltextzugriff (PDF)

Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program-Reply

JAMA internal medicine, 2020-06, Vol.180 (6), p.916

2020

Volltextzugriff (PDF)

Use of Monoclonal Antibodies for Asthma in the United States, 2003-2019

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB23

2020

Volltextzugriff (PDF)

Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-11, Vol.9 (11), p.3969-3976

2021

Volltextzugriff (PDF)

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

JAMA : the journal of the American Medical Association, 2019-02, Vol.321 (7), p.676

2019

Volltextzugriff (PDF)

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review

JAMA internal medicine, 2020-02, Vol.180 (2), p.301

2020

Volltextzugriff (PDF)

Assessing Heterogeneity of Treatment Effect in Real-World Data

Annals of internal medicine, 2023-04, Vol.176 (4), p.536-544

2023

Volltextzugriff (PDF)

Association between sodium-glucose cotransporter 2

PloS one, 2020-06, Vol.15 (6), p.e0234065

2020

Volltextzugriff (PDF)

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events

Journal of clinical epidemiology, 2019-09, Vol.113, p.11-19

2019

Volltextzugriff (PDF)

The Value of U.S. Pharmacopeial Standards: A Review of the Literature

Journal of pharmaceutical sciences, 2018-10, Vol.107 (10), p.2611-2617

2018

Volltextzugriff (PDF)

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy

Journal of clinical epidemiology, 2017-11, Vol.91, p.95-110

2017

Volltextzugriff (PDF)

Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events

Journal of clinical epidemiology, 2019-09, Vol.113, p.20-27

2019

Volltextzugriff (PDF)

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018

Annals of internal medicine, 2020-12, Vol.173 (12), p.956-963

2020

Volltextzugriff (PDF)

Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020

JAMA network open, 2021-10, Vol.4 (10), p.e2128782-e2128782

2021

Volltextzugriff (PDF)

Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019

Diabetes, obesity & metabolism, 2021-08, Vol.23 (8), p.1843-1850

2021

Volltextzugriff (PDF)

Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2021-09, Vol.20 (5), p.965-978

2021

Volltextzugriff (PDF)

Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers

JAMA network open, 2018-10, Vol.1 (6), p.e183044-e183044

2018

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

Clinical trial registration and reporting: a survey of academic organizations in the United States

Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States

CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY

Correction to: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol

Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey

Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program-Reply

Use of Monoclonal Antibodies for Asthma in the United States, 2003-2019

Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review

Assessing Heterogeneity of Treatment Effect in Real-World Data

Association between sodium-glucose cotransporter 2

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events

The Value of U.S. Pharmacopeial Standards: A Review of the Literature

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy

Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018

Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020

Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019

Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations

Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers

Suchergebnisse filtern